Summary
Bristol-Myers Squibb Company (BMY) has filed an 8-K report detailing the completion of a significant public offering of notes totaling $7.75 billion. These notes, with various maturity dates ranging from 2023 to 2050 and coupon rates from 0.537% to 2.550%, were issued under a new indenture. The primary purpose of this offering is to fund a portion of the acquisition of MyoKardia, Inc., a strategic move expected to close in the fourth quarter of 2020. This substantial debt issuance indicates BMY's proactive financing strategy to support its growth objectives, specifically the MyoKardia acquisition. Investors should note the structured nature of the financing, with a mandatory redemption clause in place if the acquisition does not close by June 30, 2021, which acts as a safeguard. The company has secured long-term funding with diverse maturity profiles, aiming to balance its capital structure while pursuing strategic expansion.
Key Highlights
- 1BMY completed a public offering of $7.75 billion aggregate principal amount of notes across multiple series with varying maturities (2023-2050) and interest rates (0.537%-2.550%).
- 2The net proceeds from the note offering are intended to fund a portion of the cash consideration for the previously announced acquisition of MyoKardia, Inc.
- 3The acquisition of MyoKardia is expected to close in the fourth quarter of 2020.
- 4The offering of notes is not conditioned on the completion of the MyoKardia acquisition.
- 5A special mandatory redemption clause requires BMY to redeem all outstanding notes at 101% of principal plus accrued interest if the MyoKardia acquisition does not close by June 30, 2021, or if BMY decides not to pursue it.
- 6The notes are governed by an Indenture, which includes customary covenants related to incurring secured debt, sale/leaseback transactions, and mergers/consolidations, as well as standard events of default.
- 7BMY also issued a press release on November 9, 2020, announcing the pricing of these notes.